These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 20234354)

  • 1. Pharmacological management of appetite expression in obesity.
    Halford JC; Boyland EJ; Blundell JE; Kirkham TC; Harrold JA
    Nat Rev Endocrinol; 2010 May; 6(5):255-69. PubMed ID: 20234354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.
    Halford JC; Harrold JA; Lawton CL; Blundell JE
    Curr Drug Targets; 2005 Mar; 6(2):201-13. PubMed ID: 15777190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT(2C) receptor agonists and the control of appetite.
    Halford JC; Harrold JA
    Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.
    Halford JC; Harrold JA; Boyland EJ; Lawton CL; Blundell JE
    Drugs; 2007; 67(1):27-55. PubMed ID: 17209663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Ueno H; Nakazato M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):753-9. PubMed ID: 24796150
    [No Abstract]   [Full Text] [Related]  

  • 7. [Recent progress and novel perspectives on obesity pharmacotherapy].
    Faria AM; Mancini MC; Melo ME; Cercato C; Halpern A
    Arq Bras Endocrinol Metabol; 2010 Aug; 54(6):516-29. PubMed ID: 20857056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and emerging drug molecules against obesity.
    George M; Rajaram M; Shanmugam E
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Centrally Acting Agents for Obesity: Past, Present, and Future.
    Coulter AA; Rebello CJ; Greenway FL
    Drugs; 2018 Jul; 78(11):1113-1132. PubMed ID: 30014268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Drug Targets in Obesity Pharmacotherapy - A Review.
    Bhat SP; Sharma A
    Curr Drug Targets; 2017; 18(8):983-993. PubMed ID: 28245771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic anti-obesity agents: past experience and future prospects.
    Halford JC; Boyland EJ; Lawton CL; Blundell JE; Harrold JA
    Drugs; 2011 Dec; 71(17):2247-55. PubMed ID: 22085383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite.
    Rodgers RJ; Holch P; Tallett AJ
    Pharmacol Biochem Behav; 2010 Nov; 97(1):3-14. PubMed ID: 20214921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-obesity drugs: a review about their effects and their safety.
    Derosa G; Maffioli P
    Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.
    Acosta A; Camilleri M; Shin A; Vazquez-Roque MI; Iturrino J; Burton D; O'Neill J; Eckert D; Zinsmeister AR
    Gastroenterology; 2015 Mar; 148(3):537-546.e4. PubMed ID: 25486131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
    Srivastava G; Apovian C
    Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of obesity: Available medications and drugs under investigation.
    Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
    Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.
    Smith SR; Blundell JE; Burns C; Ellero C; Schroeder BE; Kesty NC; Chen KS; Halseth AE; Lush CW; Weyer C
    Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E620-7. PubMed ID: 17505051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
    Ravussin E; Smith SR; Mitchell JA; Shringarpure R; Shan K; Maier H; Koda JE; Weyer C
    Obesity (Silver Spring); 2009 Sep; 17(9):1736-43. PubMed ID: 19521351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
    Roberts CA; Christiansen P; Halford JCG
    Acta Diabetol; 2017 Aug; 54(8):715-725. PubMed ID: 28421338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.